BREDA — Evibra Healthcare announced today the opening of its distribution facility located in Goes, the Netherlands.
The distribution facility provides storage, picking, packing and international shipments and is operated in accordance with the latest HACCP requirements.
The warehouse will initially be stocking Cambrooke’s Glytactin range, designed to help meet the specialized nutritional needs of patients with therapeutic or chronic medical needs (specifically, Phenylketonuria). Learn more about Glytactin »
Evibra’s Bram Wesdorp is excited about the new facility: “Today’s opening means a significant step forward for Evibra and we are particularly pleased to guarantee continuity of Cambrooke’s range of products for patients in Denmark.”
About Evibra Healthcare
Founded in 2018, Evibra Healthcare’s aim is to improve market access through importing and launching growth strategies for medical products that improve healthcare.
Evibra acquires distribution rights and in-licence contracts for products developed and/or manufactured by international organisations, or can act as local representative of companies that choose not to be locally present.
Evibra aims to (co-)develop medical products with partners by bringing the right skills and knowledge to the table.
Evibra is active in the countries of Europe, Middle East and Africa.
Evibra Healthcare is on social media, visit us on:
About Cambrooke Therapeutics
Cambrooke Therapeutics is a leader and global innovator in the field of advanced medical nutrition. We are passionate in our pursuit of improving the lives of patients by bringing new therapeutic options to those with therapeutic and chronic medical needs. We bring value to the medical community by developing, manufacturing and commercializing nutritional therapeutic options to improve patient satisfaction, clinical outcomes, and operational efficiency across a broad spectrum of diseases.
Editor’s note: Please feel free to contact the following persons for more information:
Board of Directors
+31 650 633 994
+32 486 347 583
Media & News
+31 619 546 072